Download Files:
Products Details
Product Description
– ML218-d9 is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier[1].
Web ID
– HY-103309S
Shipping
– Room temperature
Molecular Formula
– C19H17D9Cl2N2O
References
– [1]Xiang Z, et al. The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson’s Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.|[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
Molecular Weight
– 378.38
SMILES
– O=C(C1=CC(Cl)=CC(Cl)=C1)NC[C@H]2[C@@]3([H])[C@]2([H])CN(C3)CCC(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H]
Clinical Information
– No Development Reported
Research Area
– Neurological Disease
Solubility
– 10 mM in DMSO
Target
– Calcium Channel
Pathway
– Membrane Transporter/Ion Channel;Neuronal Signaling
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
